ClinicalTrials.gg
CompletedNCT06118008Updated Aug 3, 2025

A Study of HS-20094 in T2DM Participants

A Phase 2 interventional study of HS-20094 5mg and HS-20094 10mg in Type 2 Diabetes, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited — 2 open to participants now, 2 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Hansoh Pharmaceutical Group Company Limited.

Enrollment
7th of 12
54 · median 61
Started
2023
the only one that year
Phase 2
2 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 2, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

This is a randomized, placebo and active-control, multiple-dose, phase IIa trial. Patients were randomly assigned to receive HS-20094 (12 patients), placebo (3 patients), or active control drug Semaglutide injection (3 patients) in a 4:1:1 ratio to each of four dose cohorts of 5 mg, 10 mg, 15 mg, and 20 mg. HS-20094 and placebo were administered in a double-blind design by subcutaneous injection once a week for a total of four times, and the dose was gradually increased weekly (2.5-2.5-5-5 mg, 5-510-10 mg, 5-10-15-15 mg, 5-10-15-20 mg). The active control drug semaglutide was administered by open-label, titrated subcutaneous injection once a week for a total of four times, and the dose was increased gradually every week until 1.0 mg (0.25-0.5-0.5-1.0 mg). The primary study objective was to 1) Evaluate the safety and tolerability of multiple subcutaneous injections of HS-20094 in subjects with type 2 diabetes mellitus (T2DM) with or without overweight or obesity;2) Evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of multiple subcutaneous injections of HS-20094.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects,20-65 years of age at the time of signing .
  • Type 2 diabetes mellitus diagnosed for at least 3 months before the screening visit.
  • Treated with conventional lifestyle intervention and stable treatment with metformin ( ≥ 1000 mg/day) at least 3 months prior to screening 7.5-10%(both inclusive)at screening visit.

Exclusion criteria

Exclusion Criteria:

  • A history of type 1 diabetes, specific diabetes, or secondary diabetes.
  • Presence of- lab or results that may affect the evaluation of the efficacy or safety of the study drug at screening visit.
  • Acute or chronic pancreatitis at any time before screening, or serum lipase/amylase above the at screening.
  • A history of grade 2 hypoglycemia(blood glucose 3.0 mmol/L)or grade 3 hypoglycemia(hypoglycemia with a serious event of consciousness and/or physical alteration requiring assistance from another person for recovery)within 6 months before screening.
  • Diabetid ketoacidosis or hyperosmolar coma or lactic acidosis requiring hospitalization occurred within 6 months before screening.
  • Severe infection such as diabetic foot infection, pneumonia, or sepsis within 30 days before screening.
  • Uncontrollable hypertension.
  • History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening.
  • Any organ-system developed within 5 years except for cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  • Pregnant or lactating woman.
  • In the investigator's judgment, there were circumstances that affected subject safety or otherwise interfered with the evaluation of results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    HS-20094 5mg

    Drug: HS-20094 Administrated by subcutaneous injection Drug: Placebo Administrated by subcutaneous injection Drug: Semaglutide Administrated by subcutaneous injection

    Drug: HS-20094 5mg

  • Experimental
    HS-20094 10mg

    Drug: HS-20094 Administrated by subcutaneous injection Drug: Placebo Administrated by subcutaneous injection Drug: Semaglutide Administrated by subcutaneous injection

    Drug: HS-20094 10mg

  • Experimental
    HS-20094 15mg

    Drug: HS-20094 Administrated by subcutaneous injection Drug: Placebo Administrated by subcutaneous injection Drug: Semaglutide Administrated by subcutaneous injection

    Drug: HS-20094 15mg

  • Experimental
    HS-20094 20mg

    Drug: HS-20094 Administrated by subcutaneous injection Drug: Placebo Administrated by subcutaneous injection Drug: Semaglutide Administrated by subcutaneous injection

    Drug: HS-20094 20mg

Interventions

  • Administrated by subcutaneous injection

    Also known as: HS-20094 injection 5mg

  • Administrated by subcutaneous injection

    Also known as: HS-20094 injection 10mg

  • Administrated by subcutaneous injection

    Also known as: HS-20094 injection 15mg

  • Administrated by subcutaneous injection

    Also known as: HS-20094 injection 20mg

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug

    A summary of AEs and SAEs, AE leading to study discontinuation, AE severity and relation with study drug will be reported in the reported adverse events module

    Time frame: From Baseline to Day 57.

  2. The number of participants with changes of laboratory tests blood routine, urine routine, blood biochemistry, coagulation function

    Time frame: From Baseline to Day 57

  3. The changes ECG examination assessed by PR, R-R, QRS and QTcF

    12-lead electrocardiogram (ECG) parameters

    Time frame: From Baseline to Day 57

  4. The changes in Blood pressure

    Vital signs

    Time frame: From Baseline to Day 57

  5. Pulse rate

    Vital signs

    Time frame: From Baseline to Day 57

  6. Respiratory rate

    Vital signs

    Time frame: From Baseline to Day 57

  7. Temperature

    Vital signs

    Time frame: From Baseline to Day 57

Secondary outcomes

  1. Pharmacokinetics (PK): Cmax of HS-20094

    PK: Cmax of HS-20094

    Time frame: Baseline to Day 57

  2. Pharmacokinetics (PK): Tmax of HS-20094

    PK: Tmax of HS-20094

    Time frame: Baseline to Day 57

  3. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of HS-20094

    PK: AUC of HS-20094

    Time frame: Baseline to Day 57

  4. Pharmacodynamics (PD): HbA1c

    PD: change of HbA1c

    Time frame: Baseline to Day 29

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jan 2024, 7 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Nov 7, 2023
StartActual
May 31, 2023
Primary completionActual
Jan 4, 2024
CompletionActual
Jan 4, 2024
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118008
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
May 31, 2023
Primary completion
Jan 4, 2024
Completion
Jan 4, 2024
Last update
Aug 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-20094

Start the discussion